141 related articles for article (PubMed ID: 29129754)
1. CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer.
Agrawal S; Dwivedi M; Ahmad H; Chadchan SB; Arya A; Sikandar R; Kaushik S; Mitra K; Jha RK; Dwivedi AK
Nanomedicine; 2018 Feb; 14(2):327-337. PubMed ID: 29129754
[TBL] [Abstract][Full Text] [Related]
2. Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer.
Lee SY; Cho HJ
Biomacromolecules; 2019 Feb; 20(2):835-845. PubMed ID: 30566834
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
[TBL] [Abstract][Full Text] [Related]
4. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
5. Reversing P-Glycoprotein-Associated Multidrug Resistance of Breast Cancer by Targeted Acid-Cleavable Polysaccharide Nanoparticles with Lapatinib Sensitization.
Sui J; He M; Yang Y; Ma M; Guo Z; Zhao M; Liang J; Sun Y; Fan Y; Zhang X
ACS Appl Mater Interfaces; 2020 Nov; 12(46):51198-51211. PubMed ID: 33147005
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid-engineered Bcl-2 inhibitor nanocrystals for site-specific delivery to breast tumor cells.
Panwar D; Thakor P; Sharma M; Bakshi AK; Bhavana V; Srivastava V; Mishra PR; Singh SB; Mehra NK
Nanomedicine (Lond); 2023 Jun; 18(15):1005-1023. PubMed ID: 37530043
[No Abstract] [Full Text] [Related]
7. Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain.
Wan X; Zheng X; Pang X; Pang Z; Zhao J; Zhang Z; Jiang T; Xu W; Zhang Q; Jiang X
Oncotarget; 2016 Jun; 7(23):34038-51. PubMed ID: 27086917
[TBL] [Abstract][Full Text] [Related]
8. CD44 targeted redox-triggered self-assembly with magnetic enhanced EPR effects for effective amplification of gambogic acid to treat triple-negative breast cancer.
Sang M; Han L; Luo R; Qu W; Zheng F; Zhang K; Liu F; Xue J; Liu W; Feng F
Biomater Sci; 2019 Dec; 8(1):212-223. PubMed ID: 31674634
[TBL] [Abstract][Full Text] [Related]
9. Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
Werfel TA; Wang S; Jackson MA; Kavanaugh TE; Joly MM; Lee LH; Hicks DJ; Sanchez V; Ericsson PG; Kilchrist KV; Dimobi SC; Sarett SM; Brantley-Sieders DM; Cook RS; Duvall CL
Cancer Res; 2018 Apr; 78(7):1845-1858. PubMed ID: 29358172
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic Acid-Coated Camptothecin Nanocrystals for Targeted Drug Delivery to Enhance Anticancer Efficacy.
Wang J; Muhammad N; Li T; Wang H; Liu Y; Liu B; Zhan H
Mol Pharm; 2020 Jul; 17(7):2411-2425. PubMed ID: 32437163
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronic acid-coated pH sensitive poly (β-amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment.
Xu Y; Liu D; Hu J; Ding P; Chen M
Int J Pharm; 2020 Jan; 573():118637. PubMed ID: 31550511
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS
Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690
[TBL] [Abstract][Full Text] [Related]
13. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
14. Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation.
Huo ZJ; Wang SJ; Wang ZQ; Zuo WS; Liu P; Pang B; Liu K
Cancer Sci; 2015 Oct; 106(10):1429-37. PubMed ID: 26177628
[TBL] [Abstract][Full Text] [Related]
15. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles.
Liang DS; Zhang WJ; Wang AT; Su HT; Zhong HJ; Qi XR
Biomaterials; 2017 Aug; 137():23-36. PubMed ID: 28528300
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
Zhong Y; Goltsche K; Cheng L; Xie F; Meng F; Deng C; Zhong Z; Haag R
Biomaterials; 2016 Apr; 84():250-261. PubMed ID: 26851390
[TBL] [Abstract][Full Text] [Related]
17. A CD44-targeted Cu(ii) delivery 2D nanoplatform for sensitized disulfiram chemotherapy to triple-negative breast cancer.
Gao Z; Li Y; Zhang Y; An P; Chen F; Chen J; You C; Wang Z; Sun B
Nanoscale; 2020 Apr; 12(15):8139-8146. PubMed ID: 32236229
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
19. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy.
Wang S; Cao M; Deng X; Xiao X; Yin Z; Hu Q; Zhou Z; Zhang F; Zhang R; Wu Y; Sheng W; Zeng Y
Adv Healthc Mater; 2015 Jan; 4(2):281-90. PubMed ID: 25044638
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anti-tumor and anti-metastasis therapy for triple negative breast cancer by CD44 receptor-targeted hybrid self-delivery micelles.
Yang Y; Long Y; Wang Y; Ren K; Li M; Zhang Z; Xiang B; He Q
Int J Pharm; 2020 Mar; 577():119085. PubMed ID: 32001290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]